Gastroenterology Insights — Clinical Updates, Guides & Resources — Page 3

11 min readJul 30, 202628reads

Ustekinumab for Fistulising Perianal Crohn’s Disease: What the GETAID Trial Adds to Clinical Practice

For many gastroenterologists, fistulising perianal Crohn’s disease represents one of the most difficult phenotypes to manage: not because the problem is rare in specialist practice, but because clinical decision-making often requires acting with imperfect evidence. The therapeutic goal is not simply improvement in luminal inflammation. Clinicians must also address persistent drainage, recurrent sepsis risk, patient discomfort, repeated imaging, surgical coordination, and the uncertainty of whether apparent external closure reflects durable internal healing. Against this background, the GETAID trial of ustekinumab provides an important and clinically focused contribution. Published online in Gut on July 24, 2026, the article is titled “Ustekinumab for fistulising perianal Crohn’s disease: a randomised placebo-controlled trial from the GETAID.” The study was a double-blind, multicentre, randomised placebo-controlled trial evaluating ustekinumab in patients with Crohn’s disease and active draining perianal fistulas. The key question is direct and practice-relevant: in patients with active fistulising perianal Crohn’s disease, does ustekinumab improve combined clinical and radiological remission compared with placebo after standardised surgical management? Why this trial matters in a phenotype with limited RCT evidence The source article itself frames fistulising perianal Crohn’s disease as a debilitating condition with few randomised controlled trials conducted to date. That point is central to how clinicians should interpret the study. Much of perianal Crohn’s care has historically relied on a combination of extrapolation from luminal Crohn’s disease trials, subgroup analyses, real-world cohorts, and multidisciplinary experience. Those sources are valuable, but they do not replace placebo-controlled evidence in a population defined by active draining perianal fistulas. This trial is therefore not just another biologic study. It is an attempt to evaluate ustekinumab in a clinically specific phenotype, using outcomes that acknowledge both bedside examination and pelvic imaging. That distinction matters because perianal fistula assessment can be misleading if based only on external drainage. Absence of drainage may be clinically encouraging, but persistent abscess or ongoing deep tract activity on MRI may still carry clinical significance. The GETAID trial’s primary endpoint was deliberately composite: combined clinical remission, defined as absence of drainage from all external fistula openings, and radiological remission, defined as absence of abscesses larger than 2 cm on blinded central MRI, at week 12. This design choice makes the endpoint more stringent than a purely clinical drainage measure and more relevant to clinicians who manage perianal disease in collaboration with colorectal surgeons and radiologists. Study design: targeted, controlled, and clinically recognisable The trial enrolled patients with active fistulising perianal Crohn’s disease and randomised them 1:1 to ustekinumab or placebo after standardised surgical management. The ustekinumab regimen consisted of 6 mg/kg intravenously at baseline, followed by 90 mg subcutaneously at week 8 and then every 8 weeks. The study was multicentre and double-blind, conducted across 10 French centres under the Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives, or GETAID. Thirty-two patients were randomised: 16 to ustekinumab and 16 to placebo. The population was clinically challenging: 69% had prior anti-tumour necrosis factor failure. This population detail is particularly important. A trial enriched with patients who have already failed anti-TNF therapy addresses a common real-world dilemma: what to do when first-line biologic strategies for fistulising perianal Crohn’s disease have not delivered adequate control. However, the same detail also affects interpretation. Outcomes in a previously anti-TNF-exposed population may not translate directly to biologic-naïve patients, and the small sample size limits confidence in subgroup-level conclusions. The trial also included an open-label phase. At week 12, placebo non-responders could switch to ustekinumab, and ustekinumab non-responders could undergo treatment intensification during the open-label phase. This feature is clinically understandable, especially in a symptomatic fistulising disease population, but it complicates longer-term comparisons between the original randomised arms. The week-12 signal: better combined remission with ustekinumab At week 12, combined remission was achieved in 62% of patients receiving ustekinumab compared with 25% receiving placebo. The reported odds ratio was 5.1, with a 95% confidence interval of 1.07 to 24.4. This is the central efficacy signal of the trial. The direction of effect favoured ustekinumab, and the outcome was clinically meaningful because it combined absence of drainage from external openings with MRI-based absence of abscesses larger than 2 cm. The finding suggests that ustekinumab may provide short-term benefit in active fistulising perianal Crohn’s disease after standardised surgical management. The width of the confidence interval should be read carefully. A confidence interval from 1.07 to 24.4 reflects substantial uncertainty around the magnitude of effect, which is expected in a small trial with 32 randomised patients. The result supports a treatment signal but does not precisely define the size of benefit clinicians should expect in broader practice. Clinical remission alone occurred in 62.5% of the ustekinumab group compared with 31% of the placebo group, with an odds ratio of 3.75 and a 95% confidence interval of 0.84 to 16.8. Radiological remission occurred in 87.5% versus 75%, with an odds ratio of 2.7 and a 95% confidence interval of 0.34 to 21.1. These secondary outcomes are useful but should not be overinterpreted. The point estimates favour ustekinumab, but the confidence intervals are wide and include uncertainty. For practicing clinicians, the most defensible reading is that the composite week-12 endpoint provides the clearest positive signal, while the separate clinical and radiological components should be viewed as supportive but imprecise. Why the composite endpoint is clinically meaningful Perianal Crohn’s disease is not adequately captured by one measure. Drainage reflects the patient-facing and examination-facing burden of disease. MRI provides information about deeper inflammatory complications, particularly abscess. By combining both, the trial attempted to avoid the pitfall of mistaking external closure for complete disease control. The radiological component used a pragmatic threshold: absence of abscesses larger than 2 cm on blinded central MRI. This does not necessarily mean complete anatomical healing of all fistula tracts. It means that, within the trial definition, radiological remission required absence of a clinically relevant abscess threshold. Clinicians should therefore avoid describing the primary endpoint as complete fistula healing unless they define exactly what was measured. This distinction is more than semantic. Patients may ask whether a treatment “heals the fistula.” The trial supports a short-term improvement in a combined clinical and MRI-based endpoint, not a universal guarantee of durable fistula closure or elimination of future surgical need. The source details available do not justify claims about complete tract resolution, long-term prevention of recurrence, or superiority over other active biologics. Interpreting the week-48 findings without overstating durability The open-label phase provides additional context but less controlled evidence than the double-blind week-12 comparison. Nine placebo-group patients switched to ustekinumab during the open-label phase. Combined remission rates at week 48 were reported as 50% in the placebo arm and 31% in the ustekinumab arm. These week-48 figures should be interpreted cautiously. Because non-responders could switch or intensify after week 12, the original randomised comparison becomes less straightforward. The lower week-48 combined remission rate in the original ustekinumab arm should not be read in isolation as evidence of loss of efficacy, nor should the 50% rate in the placebo arm be interpreted as placebo superiority. Treatment switching and intensification alter the meaning of arm-level comparisons. The most reliable inference remains the short-term randomised comparison at week 12. The longer-term data raise important clinical questions about durability, optimisation, timing of intensification, and the role of ongoing surgical or imaging-based management, but they do not provide a clean placebo-controlled maintenance comparison. What clinicians can reasonably conclude The authors concluded that the findings suggest greater short-term clinical benefit with ustekinumab compared with placebo and support its use in patients with active fistulising perianal Crohn’s disease. That conclusion is appropriately measured. It does not claim that ustekinumab is curative, that it replaces surgical management, or that it should be considered definitively superior to other biologic strategies. For gastroenterologists, the trial strengthens the evidence base for considering ustekinumab in active fistulising perianal Crohn’s disease, particularly in a population where many patients had prior anti-TNF failure. It also reinforces the importance of multidisciplinary management, because patients entered the trial after standardised surgical management. The medical therapy signal should therefore be understood as occurring within a structured care pathway rather than as isolated biologic treatment. This is not evidence that ustekinumab should be used without adequate assessment for abscess, seton need, or surgical input. It is also not a direct comparison with anti-TNF therapy, vedolizumab, IL-23 inhibitors, antibiotics, stem-cell therapy, or surgical approaches. The trial compared ustekinumab with placebo under the trial protocol. What clinicians should not conclude Several conclusions would go beyond the source. First, the trial does not establish ustekinumab as the best biologic for fistulising perianal Crohn’s disease. No active comparator was included. A placebo-controlled design answers whether ustekinumab performs better than placebo under study conditions; it does not rank ustekinumab against other treatments. Second, the trial does not prove that ustekinumab prevents recurrence, avoids surgery, or reduces hospitalisation. Those outcomes are not supported by the source details available. Third, the trial should not be presented as definitive for all patients with perianal Crohn’s disease. The sample was small, and most patients had prior anti-TNF failure. The findings may be most relevant to a specialist population with active draining disease managed in experienced centres. Fourth, clinicians should not infer that week-48 arm-level results provide a simple maintenance efficacy estimate. The open-label crossover and intensification design makes those later outcomes clinically informative but methodologically less definitive than the week-12 endpoint. Strengths that make the study clinically useful Several features increase the value of the GETAID trial. The study was randomised, double-blind, placebo-controlled, and multicentre. It focused specifically on active draining fistulising perianal Crohn’s disease rather than treating perianal disease as a small subgroup within a luminal Crohn’s trial. It used a clinically meaningful composite endpoint that incorporated both external drainage and blinded central MRI assessment for abscess. It also embedded treatment after standardised surgical management, reflecting the multidisciplinary reality of perianal Crohn’s care. The inclusion of a high proportion of patients with prior anti-TNF failure is another clinically relevant feature. These are precisely the patients in whom clinicians often need additional evidence to support treatment selection. Limitations that should shape practice interpretation The most obvious limitation is size. Thirty-two randomised patients is a small trial, particularly for a heterogeneous condition such as fistulising perianal Crohn’s disease. Small trials can detect important signals, but they are vulnerable to imprecision. The wide confidence intervals around several outcomes reflect that uncertainty. Second, the open-label phase limits clean interpretation of longer-term outcomes. Crossover and intensification are ethically and clinically understandable but reduce the ability to interpret week-48 arm comparisons as a sustained randomised treatment effect. Third, the available source details do not provide enough information to make claims about specific fistula anatomy, quality of life, adverse event patterns, need for further procedures, or long-term recurrence. Those may be addressed in the full article, but they should not be invented or assumed from the abstract-level information. Fourth, the trial’s findings apply to the studied intervention and protocol: intravenous induction followed by subcutaneous maintenance dosing after standardised surgical management. Extrapolation to different dosing strategies, earlier use, combination approaches, or non-specialist settings requires caution. How this may influence future research The GETAID trial strengthens the rationale for larger, phenotype-specific trials in perianal Crohn’s disease. Future studies should clarify durability, optimal timing of biologic initiation relative to surgical control, the value of dose intensification, predictors of response, MRI-based definitions of deeper healing, and patient-centred outcomes such as pain, drainage burden, continence concerns, work impairment, and quality of life. The trial also highlights the need for standardised endpoints. A combined clinical-radiological endpoint may be more clinically meaningful than drainage alone, but future research should continue refining what constitutes true healing, meaningful improvement, and durable remission in fistulising disease. Clinical Takeaway The GETAID ustekinumab trial provides a focused, randomised placebo-controlled signal that ustekinumab improves short-term combined clinical and radiological remission in active fistulising perianal Crohn’s disease after standardised surgical management. The week-12 composite remission rate favoured ustekinumab, but the small sample size and wide confidence intervals mean the magnitude of benefit remains uncertain. Longer-term data are clinically interesting but harder to interpret because of open-label crossover and treatment intensification. For clinicians, the study supports ustekinumab as an evidence-backed option in this difficult phenotype, especially when anti-TNF failure has occurred. It should not be framed as definitive proof of durable fistula healing, superiority over other therapies, or replacement for multidisciplinary surgical assessment. The most responsible interpretation is that ustekinumab now has placebo-controlled trial evidence suggesting short-term benefit in active fistulising perianal Crohn’s disease, while durability, optimisation, comparative positioning, and implementation remain important unanswered questions. Five Key Clinical Takeaways The GETAID trial was a double-blind, multicentre, randomised placebo-controlled trial of ustekinumab in active fistulising perianal Crohn’s disease. Thirty-two patients were randomised across 10 French centres; 69% had prior anti-TNF failure, making the population clinically relevant but specialised. At week 12, combined clinical and radiological remission occurred in 62% with ustekinumab versus 25% with placebo. The primary endpoint combined absence of drainage from all external fistula openings with absence of abscesses larger than 2 cm on blinded central MRI. The study supports a short-term treatment signal for ustekinumab, but small sample size, wide confidence intervals, and open-label crossover limit conclusions about durability and comparative positioning. Source Reference and Link Wils P, Nancey S, Messmer E, et al.; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Ustekinumab for fistulising perianal Crohn’s disease: a randomised placebo-controlled trial from the GETAID. Gut. Published online July 24, 2026. DOI: 10.1136/gutjnl-2026-339158. Trial registration: NCT04496063.

GastroAGI TeamRead more

5 min readJul 29, 202614reads

Maddrey's Discriminant Function: How to Calculate It Correctly

A resident calculates a DF of 28 on a patient with suspected alcoholic hepatitis, rounds the prothrombin time control down for convenience, and misses the steroid-eligible cutoff by four points that shouldn't have been there. The formula has two inputs and one constant - and it's still one of the most commonly miscalculated bedside scores in hepatology. This post walks through exactly how to calculate it, which control PT to use, and where the errors creep in. Maddrey's discriminant function (MDF) is calculated as 4.6 × (patient's prothrombin time in seconds − control prothrombin time in seconds) + total bilirubin in mg/dL . Every input looks straightforward until you're the one entering it: which control PT your lab uses isn't standardized, bilirubin units get mixed up between mg/dL and µmol/L, and a lab-to-lab difference in control PT of even 1–2 seconds can shift the calculated DF enough to change whether a patient crosses the 32-point threshold. Getting the Maddrey discriminant function formula right isn't a triviality before the clinical decision - it's the clinical decision, since the entire score exists to answer one binary question at one specific cutoff. Check out: MELD-Na score interpretation The Formula, Step by Step Start with the two lab values you need: total bilirubin (mg/dL) and prothrombin time (seconds), plus your lab's control PT - the reference PT value your coagulation lab uses for a healthy control, not the patient's own baseline. Subtract the control PT from the patient's measured PT, multiply that difference by 4.6, then add the total bilirubin. So a patient with a PT of 22 seconds, a lab control PT of 12 seconds, and a bilirubin of 9.8 mg/dL calculates as 4.6 × (22 − 12) + 9.8 = 55.8. That patient clears the DF >32 threshold associated with roughly 35–45% one-month mortality without treatment, making them a candidate for corticosteroid consideration pending the usual contraindication screen. If bilirubin is reported in µmol/L rather than mg/dL, divide by 17 first - skipping that conversion is one of the most common calculation errors and produces a wildly inflated score. Case in point A 47-year-old man with heavy alcohol use is admitted with jaundice. His bilirubin returns at 9.8 mg/dL and his PT at 21 seconds. The admitting team uses their hospital lab's stated control PT of 12.5 seconds and calculates a DF of 44.9 - clearly above 32. A senior resident recalculates using 13.5 seconds, the control value used in a different published study she remembers, and gets a DF of 42.7. Both numbers land the patient in the same clinical category, but the discrepancy prompts the team to actually check which control PT their own institution's coagulation lab reports. That check matters more than it seems. A retrospective review of 882 patients found that the specific control PT used in the calculation affected whether patients were flagged for steroid consideration, even though it didn't change 30-day survival outcomes - meaning the choice of control PT can move a patient across the treatment-eligibility line without reflecting a real difference in their disease severity. Confirming your institution's control PT value once, rather than assuming a number from memory or a paper, removes that variability entirely. Where the Score Gets Miscalculated in Practice The most frequent real-world error isn't the arithmetic - it's using the wrong control PT, either an outdated value, a different lab's published constant, or, occasionally, the patient's own PT from a prior admission mistaken for a control value. Always use your own coagulation lab's stated control PT, printed on most PT/INR reports or available from lab services directly, not a number memorized from a textbook or a different hospital's protocol. The second common error is unit mismatch on bilirubin, particularly in settings that report in SI units by default. The third, more subtle error is timing: calculating the DF from labs drawn before adequate resuscitation or before an evolving infection is treated can produce a transiently elevated score that doesn't reflect the patient's true baseline severity a day or two later. None of these errors are in the formula itself - the formula is fixed and simple. They're all in the inputs, which is exactly why the score is so easy to get wrong despite being so easy to compute. A frequently overlooked point Clinicians sometimes recalculate the DF daily expecting it to track clinical trajectory the way MELD does, and get confused when a patient looks worse but their DF barely moves. The DF wasn't designed as a continuous severity tracker - it's a single-timepoint threshold test, calculated once at presentation to answer one question. Trending it daily like a MELD score isn't wrong exactly, but it's asking a static eligibility gate to do the job of a dynamic prognostic score, and the number will disappoint you if that's what you expect from it. Bottom line for clinical practice Formula: 4.6 × (patient PT − control PT in seconds) + total bilirubin in mg/dL. Confirm your institution's actual control PT value before calculating - don't use a remembered or textbook figure. Convert bilirubin from µmol/L to mg/dL (divide by 17) before plugging it into the formula if your lab reports in SI units. A DF above 32 is the threshold associated with significant short-term mortality and the trigger for steroid-candidacy evaluation. Calculate once at presentation on stable, resuscitated labs - the DF is a single-timepoint threshold, not a daily trending score. Once you have the number, the harder question is what to do with it - our post on Maddrey's discriminant function and steroid candidacy covers exactly that decision, including the contraindications that make a DF above 32 reversible. And if a patient's picture involves both alcoholic hepatitis and cirrhosis, MELD-Na score interpretation breaks down which score answers which question. Run the calculation through GastroAGI directly and skip the control-PT guesswork entirely.

GastroAGI TeamRead more

8 min readJul 28, 202621reads

Artificial General Intelligence in Healthcare: What Gastroenterologists and Hepatologists Should Know Now

Could a future AI system integrate symptoms, laboratory data, longitudinal records, imaging, pathology, remote monitoring, and the literature well enough to act as a truly general clinical partner rather than a point tool? That is the unresolved question sitting underneath today’s excitement about artificial general intelligence in healthcare. The source base reviewed here suggests that healthcare is moving in that direction conceptually, but it also shows that most current deployment remains much closer to narrow AI or clinically bounded AI than to human-level general reasoning. For gastroenterologists, hepatologists, fellows, and researchers, the right starting point is therefore not triumphalism. It is disciplined curiosity. Healthcare’s attraction to more capable AI is easy to understand. Several of the supplied sources describe a care environment overwhelmed by data: electronic health records, laboratory results, imaging, sensor streams, pathology, medical literature, and patient-generated information. LTTS points to electronic medical records, PACS, hospital systems, claims data, and surveys as major data streams, while Emorphis emphasizes records, labs, imaging, genomics, wearable data, claims, and clinical notes. HRS similarly frames AI’s appeal around improving decisions, supporting human judgment, and increasing efficiency. For subspecialists who routinely synthesize fragmented information across time, the clinical problem is recognizable even before one reaches the AGI question. A useful clarification comes from Aidoc and Emorphis. Aidoc distinguishes healthcare AI from clinical AI : healthcare AI includes administrative and operational tools, whereas clinical AI is more directly aimed at patient care and clinician decision-making. Emorphis, by contrast, draws the line between today’s narrow AI and a hypothetical AGI that could reason across multiple domains, adapt to new scenarios, and integrate diverse types of information. That distinction matters for clinician expectations. Much of what is already being implemented in hospitals today belongs to the narrower side of that spectrum: image triage, workflow support, notification systems, documentation, or patient routing. The stronger the claim sounds like generalized physician reasoning, the weaker the evidence base becomes in the source set you provided. One of the most clinically intuitive scenarios is multimodal diagnostic synthesis . Emorphis argues that an AGI-capable system could combine imaging, history, genetics, labs, lifestyle, and environmental context rather than interpret each stream in isolation. LTTS similarly describes AI-enabled EHRs that support suggestive diagnosis, disease risk estimation, and progression pathways, and it highlights radiology and pathology as areas where AI may improve speed and accuracy. Translated for a gastroenterology or hepatology reader, the attraction is obvious: many real patients do not present as single-data-type problems. They arrive with symptoms, prior procedures, medication exposure, serial labs, pathology, imaging, and changing risk factors. The source base supports the idea that broader data integration could improve diagnostic support, but it does not establish GI-specific performance, causation, or superiority over specialist care. A second scenario is personalized treatment planning . Emorphis describes AGI as potentially able to evaluate prior treatment responses, monitor real-time change, predict complications, and recommend dynamic adjustments. LTTS puts similar weight on precision medicine, especially where genomics, environment, lifestyle, and history may allow a shift away from one-size-fits-all care. The Medium piece extends the same argument to individualized treatment selection. For clinicians in chronic digestive disease, this is an appealing vision: not because current sources prove it in GI, but because the logic of individualized longitudinal care is already central to subspecialty practice. What the sources support is a conceptual pathway toward more tailored recommendations. What they do not support is any conclusion that AGI has already validated treatment personalization in gastroenterology or hepatology, or that it should alter guideline-based care today. A third scenario concerns care navigation, chronic disease follow-up, and remote monitoring . The BDJ paper describes AI-enabled personalized health information, virtual consultations, and remote monitoring as ways of improving access and allowing earlier intervention. Emorphis argues that wearable and home-device data could help detect deterioration and trigger proactive intervention. Infermedica’s AI-in-healthcare category emphasizes care navigation and digital triage, and HRS frames the broader future of AI around a shift from reactive to preventive care. For GI and liver clinicians, this is one of the more practical areas to watch because it starts from workflow and access, not from claims of autonomous diagnosis. Still, the source set remains largely descriptive. It supports the plausibility of earlier outreach and better routing, but it does not provide GI-specific evidence that such systems reduce decompensation, flare rates, procedure delays, or hospitalizations. A fourth and more immediately tangible area is image and tissue interpretation , although this is arguably where the conversation is more about advanced clinical AI than AGI. Dave and Patel discuss AI in medical radiology and diagnostic histopathology, including image analysis, automated tissue segmentation, predictive analysis, and quality control. LTTS likewise describes AI contributions to medical imaging and pathology review, and Aidoc’s guide emphasizes the distinction between broader healthcare AI and patient-care-focused clinical AI. For clinician readers, this matters because it is closer to the present tense. The source set suggests that imaging and pathology are among the most concrete domains for implementation because the task boundaries are clearer and the inputs are more structured. But that should not be mistaken for proof that “general intelligence” has arrived. The most credible near-term reading is that bounded, validated, workflow-embedded tools are a more realistic bridge than full-spectrum AGI. A fifth scenario is administrative relief and operational redesign . Emorphis lists workforce planning, scheduling, supply chain management, revenue cycle optimization, and workflow automation among likely AGI-related applications. LTTS similarly discusses appointment scheduling, billing, insurance claims, coding, demand forecasting, and regulatory monitoring. The Medium article adds patient flow and staffing optimization to the human-AI partnership theme. HRS, meanwhile, argues that AI is more likely to enhance clinicians than replace them. This cluster of use cases deserves more attention than it often gets in academic discussions because operational friction is itself a clinical issue. When documentation, routing, coding, or follow-up logistics fail, patient care degrades. Even so, operational usefulness should not be conflated with validated clinical outcome benefit. The sources support probable workflow value; they do not prove downstream causal improvements in specialty outcomes. A sixth scenario is research acceleration and drug development . Emorphis and the Medium article describe AGI as a possible catalyst for hypothesis generation, target identification, drug interaction prediction, and simulation of clinical trial outcomes. LTTS adds in silico testing and large-scale analysis of clinical trial and real-world datasets. For researchers in digestive disease and hepatology, this may be one of the most strategically important long-range themes because the literature burden, biomarker complexity, and translational pipeline are already difficult to manage with conventional analytic approaches. Yet here again the evidence posture matters. The sources support a future-oriented claim that AI could accelerate discovery; they do not document a completed AGI-driven transformation in specialty therapeutics, and they do not establish whether faster model-driven discovery reliably translates into safer or better treatments. The source set also raises an underappreciated domain for clinician leaders: education and professional adaptation . Dave and Patel explicitly extend the AI conversation into medical and dental education and even scientific publishing. HRS notes that healthcare workers will need stronger fluency in data and analytics as AI becomes more embedded in care delivery. Infermedica’s 2025 materials add a complementary emphasis on validation and regulated deployment, suggesting that the clinical task is not merely learning to use AI tools, but learning to interrogate them: What was validated, for whom, under what regulatory framework, and with what failure modes? That mindset may be especially important for fellows and early-career clinicians, because the real change may be less about replacing decision-makers and more about changing what competent decision-making requires. So what should clinicians conclude from this evidence base? First, there is consistent cross-source agreement that AI’s opportunities in healthcare cluster around data synthesis, earlier identification of risk, personalization, triage, monitoring, clinical support, workflow redesign, and research acceleration. Second, there is also cross-source agreement that privacy, bias, transparency, safety, patient trust, and regulation are not side issues; they are core adoption constraints. Emorphis names privacy, explainability, bias mitigation, and trust directly. LTTS emphasizes privacy, security, and compliance. Infermedica’s recent validation- and certification-focused materials show that some parts of the field are moving from abstract enthusiasm toward trust-building and quality systems. What clinicians should not conclude is equally important. The current source set does not justify the claim that AGI has been proven to improve GI-specific outcomes. It does not show that AGI should replace specialist judgment, that it is ready to redefine standards of care, or that conceptual scenarios in personalization and multimodal reasoning already constitute established clinical guidance. Most of the material is scenario-driven, strategic, or implementation-oriented. Even the strongest academic source is a narrative perspective, not a comparative effectiveness study. That difference is the line between possibility and proof. For practice and research, the most responsible path is therefore incremental and evidence-seeking. In the near term, GI and hepatology leaders should probably be most interested in clinically bounded tools with transparent workflows, measurable task definitions, and some validation or regulatory maturity. In the medium term, the more ambitious promise is connective intelligence: systems that can unify records, imaging, pathology, monitoring, and literature into actionable support. In the long term, the AGI question remains open. But if that future arrives, it will still have to earn clinical trust the old-fashioned way: by showing where it works, where it fails, and whether it improves decisions, workflows, or patient outcomes in defined settings rather than in abstract prose. Key clinical takeaways The strongest scholarly source in the supplied set is a peer-reviewed perspective paper , not a clinical trial, so the overall evidence base is best read as conceptual and implementation-oriented rather than outcomes-proving . The most realistic near-term benefits for clinicians appear to be bounded clinical AI and workflow tools such as diagnostic support, digital triage, remote monitoring, pathology or imaging support, and documentation or operational automation. The supplied sources consistently frame future value around multimodal data integration, personalization, earlier detection, and proactive care , but they do not establish GI-specific causal benefit or justify changing specialty standards of care. For clinician adoption, validation, explainability, privacy, bias mitigation, regulatory compliance, and trust are not secondary concerns; they are central determinants of whether an AI tool should be used at all. The most defensible practice stance today is to treat AGI as a strategic horizon while evaluating present-day tools task by task, with clear attention to workflow fit, clinical governance, and specialty-specific evidence gaps. Source references Primary peer-reviewed source: Dave M, Patel N. Artificial intelligence in healthcare and education . British Dental Journal. May 2023; 234(10):761–764.

GastroAGI TeamRead more

5 min readJul 28, 202667reads

Rome V Criteria for IBS: What the New Frequency Threshold Actually Changes

A 29-year-old presents with cramping abdominal discomfort - not quite pain - three days a month, tied loosely to altered stool form. Under Rome IV, she doesn't meet criteria for IBS. Under Rome V, published May 2026, she does. Same patient, same symptoms, different diagnosis. This post walks through exactly what changed and why it matters for how you code, treat, and counsel patients starting now. Rome IV tightened IBS diagnosis considerably from Rome III, requiring abdominal pain - not discomfort - at least one day per week over the preceding three months. That threshold was defensible on paper but never sat well in clinic: patients who plainly had IBS by every other measure kept landing in "unspecified functional bowel disorder" because their symptom diary didn't clear the bar. Rome V is a direct response to that mismatch, part of the broader overhaul of the disorders of gut-brain interaction framework published in May 2026 . The core diagnostic criteria for Rome V IBS now better reflect how patients actually present, and getting the threshold change right matters for coding accuracy, trial eligibility, and - increasingly - for not dismissing patients whose symptoms are real but don't fit last decade's cutoff. What Changed From Rome IV to Rome V Two specific revisions define the update. First, abdominal discomfort is back as a qualifying symptom alongside pain - Rome IV had dropped discomfort entirely, requiring pain specifically. That exclusion turned out to systematically underrepresent patients in populations where discomfort, rather than frank pain, is the dominant descriptor of their symptoms. Second, and more consequential in practice: the frequency requirement dropped from at least one day per week to at least three days per month over the same three-month window. This wasn't an arbitrary loosening. A global epidemiology study spanning more than 50,000 individuals found the stricter Rome IV threshold cut measured IBS prevalence roughly in half - from around 10% down to 4% - not because fewer people had the condition, but because the weekly-pain requirement screened out patients with clinically significant, intermittent symptoms. The rest of the IBS framework - the requirement that symptoms relate to defecation, a change in stool frequency, or a change in stool form, with at least two of three present - carries over from Rome IV largely intact. This is a recalibration of sensitivity, not a rewrite of the underlying construct. Case in point A 34-year-old woman has intermittent lower abdominal cramping that partially resolves after a bowel movement, occurring on roughly three days most months, alongside loose stools on those same days. She has no alarm features - no weight loss, no rectal bleeding, no nocturnal symptoms, no family history of IBD or colorectal cancer, and basic labs are unremarkable. Under Rome IV, her symptom frequency falls short of the once-weekly pain threshold, and she's technically classified as an unspecified functional bowel disorder despite a textbook clinical picture. Reassessed under Rome V, she meets criteria for IBS with predominant diarrhea outright. The diagnosis doesn't change her workup - she still didn't need a colonoscopy based on her age and lack of alarm features either way - but it changes what you tell her, how you code the encounter, and whether she's eligible for IBS-specific trials or FDA-approved IBS therapies that require a formal diagnosis to prescribe. Applying the New Threshold in Practice The practical shift is in how you take the history. Where a Rome IV-era clinician might ask "how often do you get pain, and is it at least weekly," the Rome V-appropriate question is broader: "how often do you notice pain or discomfort, and does three days a month sound right." Patients who previously answered "off and on, maybe a few times a month" and got waved off as non-diagnostic now clear the bar. This matters most for two groups: patients with genuinely intermittent symptoms who were previously under-coded, and patients whose native symptom vocabulary leans toward "discomfort" or "unease" rather than "pain" - a pattern noted more often in some populations than others, which was part of the rationale for reincluding discomfort in the first place. The subtype classification itself - IBS-C, IBS-D, IBS-M, IBS-U, based on predominant stool pattern - is unchanged. What's changed is simply how many patients clear the gate to be classified at all. As with Rome IV, the diagnosis remains clinical: alarm features still warrant investigation regardless of how neatly a patient fits the symptom criteria. A frequently overlooked point The instinct with any loosened diagnostic threshold is to worry about overdiagnosis, but that's not really the risk here - the risk under Rome IV was underdiagnosis, and Rome V is a correction toward accuracy, not a lowering of the bar for convenience. The patients newly captured by the three-day-a-month threshold aren't marginal cases invented by a committee; they're the same patients who were always symptomatic and simply weren't being counted. If anything, clinicians who kept a mental Rome III-era threshold running in the background - treating patients as IBS based on clinical gestalt even when Rome IV technically excluded them - will find Rome V finally matches what they were already doing. Bottom line for clinical practice Recheck your mental frequency threshold: Rome V requires symptoms at least three days per month, not one day per week, over the preceding three months. Abdominal discomfort now qualifies alongside pain - don't discount a patient because they describe unease rather than frank pain. The two-of-three defecation-related criteria (relation to bowel movement, change in stool frequency, change in stool form) are unchanged from Rome IV. IBS subtyping (IBS-C, IBS-D, IBS-M, IBS-U) is unaffected - only the qualifying threshold to reach a diagnosis has moved. Alarm features still override symptom criteria entirely; Rome V doesn't change your threshold for further workup. Running a borderline case through the new thresholds by hand is exactly the kind of check GastroAGI is built for. And once a patient is confirmed under the new criteria, treatment selection is its own decision tree - our post on SNRIs and other neuromodulators in IBS covers that next step. Walk a case through GastroAGI directly and it'll flag whether a patient clears Rome V criteria, no manual recalculation required. Try GastroAGI .

GastroAGI TeamRead more

10 min readJul 25, 202621reads

Fluorescence-Guided Molecular Imaging in GI Oncology: What the AGA Lumicell Spotlight Signals for Future Cancer Resection

For every clinician involved in gastrointestinal cancer care, one question remains central after a tumor is removed: was all clinically meaningful disease actually cleared? Surgeons, therapeutic endoscopists, oncologists, pathologists, radiologists, and gastroenterologists approach this question from different angles. The surgeon sees the operative field. The endoscopist sees mucosal and submucosal planes. The pathologist sees the specimen after removal. The oncologist thinks in terms of recurrence risk and systemic disease. Yet the decision that matters most to patients is often made across time: cancer is removed during the procedure, but certainty about residual microscopic disease may come later. A recent American Gastroenterological Association innovation spotlight, titled “Startup spotlight: Lumicell – illuminating the future of surgical oncology,” published on July 20, 2026 , brings this unresolved problem into focus. The piece highlights Lumicell, a 2026 AGA Shark Tank participant developing fluorescence-guided molecular imaging for real-time cancer detection during surgery. The technology is not currently presented as established GI oncology practice. Rather, the AGA spotlight frames it as an innovation with potential implications for surgical oncology and, possibly in the future, advanced endoscopic interventions. The clinical problem: residual disease is often a delayed diagnosis The AGA spotlight identifies one of the most difficult problems in solid tumor surgery: knowing before the operation ends whether all cancer has truly been removed. Despite advances in imaging and pathology, microscopic residual disease may remain undetected during surgery. In breast-conserving surgery, this uncertainty can lead to second operations after postoperative pathology identifies positive margins. The AGA article notes that similar challenges exist in gastrointestinal oncology, where clinicians must balance oncologically sound resection with preservation of healthy tissue. That balance is especially relevant to GI cancer care. Colorectal, gastric, pancreatic, and esophageal cancer operations often require careful trade-offs between complete tumor clearance and preservation of organ function, anastomotic integrity, quality of life, and procedural morbidity. Even in advanced endoscopy, the same logic applies at a different scale: endoscopic mucosal resection, endoscopic submucosal dissection, and endoscopic full-thickness resection increasingly aim to remove early neoplasia while preserving anatomy. The limitation of current practice is not that clinicians lack skill or imaging altogether. It is that intraoperative and intraprocedural decision-making remains constrained by what can be seen, palpated, sampled, or later confirmed by pathology. The AGA spotlight describes current surgical reliance on visual inspection, palpation, frozen section, and permanent pathology, while noting that these approaches may either lack sensitivity or not be available in real time. What the AGA spotlight investigated This update is best classified as society innovation news , not a clinical trial report, guideline, systematic review, or practice recommendation. The article profiles Lumicell as a 2026 AGA Shark Tank participant and describes the company’s technology, regulatory milestone in breast-conserving surgery, and potential relevance to broader surgical oncology. The technology focus is fluorescence-guided molecular imaging for real-time cancer detection during surgery . The AGA source describes Lumicell as founded in 2008, headquartered in Newton, Massachusetts, and at a commercial stage with an FDA-approved platform for breast cancer resection while GI oncology work is ongoing. That distinction is essential. The population directly connected to FDA approval in the AGA article is breast-conserving surgery, not GI cancer. The GI relevance is forward-looking and translational. The article does not report a completed GI oncology randomized trial, GI-specific diagnostic accuracy estimates, recurrence outcomes, margin-negative resection rates, or survival data. Therefore, any GastroAGI interpretation must treat the GI implications as plausible future directions rather than established clinical benefit. The technology: molecular signal at the surgical cavity Lumicell’s platform, as described by AGA, combines an intravenously administered, protease-activated fluorescent imaging agent, LUMISIGHT™ / pegulicianine , with a handheld imaging device that detects fluorescence within the surgical cavity after the primary tumor has been removed. The purpose is to help surgeons visualize suspicious residual tissue during the same operation rather than waiting days for pathology results. This concept is important because it shifts imaging from anatomy alone toward molecular activity. The AGA article frames the platform as a combination of molecular imaging, optical engineering, and real-time clinical decision support. In practical terms, the promise is not merely a brighter operative field. It is the possibility of identifying tissue that may carry a tumor-associated molecular signal and using that information while there is still an opportunity to resect additional tissue. However, the clinical word “suspicious” matters. Fluorescence is not the same as a final histopathological diagnosis. The AGA spotlight does not state that fluorescence-guided imaging replaces pathology, nor does it provide GI-specific accuracy metrics. For clinicians, the correct interpretation is that molecular imaging could become an adjunct to operative or endoscopic judgment, not a substitute for pathological confirmation. Why GI clinicians should care, even before GI adoption At first glance, a technology approved for breast-conserving surgery may seem distant from everyday gastroenterology. But the AGA spotlight argues that the underlying concept has broader implications for surgical oncology, including gastrointestinal malignancies where complete tumor removal remains fundamental to outcomes. This is where the update becomes relevant for gastroenterologists and GI oncologists. Modern GI cancer care is increasingly multidisciplinary. Gastroenterologists diagnose and stage disease, identify high-risk lesions, perform therapeutic resections for selected early cancers, manage surveillance, and participate in MDT decisions about surgery, oncology, and follow-up. Technologies that improve intraoperative or intraprocedural detection of residual neoplasia could eventually affect these workflows. The AGA article specifically points toward complex colorectal, gastric, pancreatic, and esophageal cancer resections, where complete tumor removal must be balanced against preserving normal tissue. It also notes that molecular imaging may eventually influence advanced endoscopic interventions as EMR, ESD, and full-thickness resection become more sophisticated. That “eventually” should not be ignored. It signals potential, not readiness. But it is a relevant potential because advanced endoscopy is moving toward increasingly precise, organ-preserving oncologic therapy. Better visualization of residual neoplasia could theoretically support more complete resection, better margin assessment, or more informed decisions about additional therapy. The current AGA source does not prove those outcomes in GI practice. The AGA innovation ecosystem around this update The Lumicell spotlight sits within a broader AGA strategy to connect clinicians, researchers, entrepreneurs, and industry around GI innovation. AGA’s New Technology & Techniques page states that the organization is committed to driving innovation so future gastroenterologists have new tools to care for digestive disease patients. It also lists the AGA Incubator Showcase at DDW 2026 and describes AGA’s partnership with MATTER, through which members can access resources for building health care solutions. AGA also describes a GI Opportunity Fund , launched with Varia Ventures, dedicated to investing in fast-growing early-stage companies in the GI space. The same AGA innovation page lists examples of supported companies working across AI-fueled endoscopic procedure recording and trial recruitment, attachable EUS platforms, unsedated transnasal endoscopy, virtual digestive care, and other digestive disease technologies. This matters because innovation in GI is no longer limited to devices used during procedures. It now includes AI-enabled documentation and recruitment, minimally invasive diagnostics, care delivery platforms, molecular imaging, procedure-based therapeutics, and reimbursement-aware implementation strategies. AGA’s presidential innovation coverage from DDW 2026 similarly described innovation as spanning technology, care delivery, workforce development, genomics, proteomics, AI, and policy advocacy. For clinicians, this broader ecosystem matters because the success of a technology rarely depends on performance alone. Adoption also requires training, workflow fit, reimbursement, regulatory clarity, safety monitoring, equitable access, and evidence that the tool improves clinically meaningful outcomes. What clinicians can reasonably infer From the AGA spotlight, clinicians can conclude that fluorescence-guided molecular imaging is being actively developed as a real-time cancer detection strategy and that Lumicell’s platform has achieved FDA approval for breast-conserving surgery. The AGA article states that Lumicell received simultaneous FDA approval in April 2024 for both its imaging agent and imaging system, supported by a multicenter clinical development program in breast-conserving surgery. Clinicians can also conclude that AGA considers this type of platform relevant to the GI innovation community because of its potential implications for surgical oncology and possibly advanced endoscopic interventions. The update explicitly links the concept to colorectal, gastric, pancreatic, and esophageal cancer resections and to the broader evolution of EMR, ESD, and full-thickness resection. But clinicians should not infer GI clinical efficacy from this spotlight. The AGA source does not present GI-specific trial results. It does not establish that fluorescence-guided molecular imaging reduces repeat surgery in GI cancers, improves R0 resection rates, reduces recurrence, improves survival, or changes endoscopic management. Those would require GI-specific prospective evidence. What this does not mean for current practice This update should not be interpreted as a recommendation to incorporate Lumicell’s platform into routine GI oncology or advanced endoscopy practice today. The AGA source describes GI oncology work as ongoing, while the current FDA-approved platform referenced is for breast cancer resection. It also should not be interpreted as evidence that molecular imaging can replace frozen section, permanent pathology, endoscopic assessment, cross-sectional imaging, or multidisciplinary review. The technology is described as providing real-time decision support, not definitive histology. For gastroenterologists, the appropriate stance is informed caution. The field should watch fluorescence-guided molecular imaging closely, particularly as organ-preserving approaches expand. But it should demand the same evidence standards expected of other cancer technologies: clearly defined indications, diagnostic accuracy, effect on management decisions, patient-centered outcomes, procedural safety, cost-effectiveness, and reproducibility across centers. Evidence gaps that matter before GI implementation Several evidence gaps remain. First, GI-specific diagnostic performance is not established in the AGA spotlight. Future studies would need to define sensitivity, specificity, positive predictive value, and negative predictive value for residual cancer detection in specific GI tumors and procedural contexts. Second, clinical utility must be demonstrated. A test can detect a signal without improving outcomes. The clinically relevant question is whether fluorescence-guided imaging changes intraoperative or endoscopic decisions in ways that improve margin status, reduce repeat procedures, avoid unnecessary tissue removal, or improve oncologic outcomes. Third, anatomical and biological differences across GI cancers matter. Colorectal, gastric, pancreatic, and esophageal tumors differ in operative field, stromal environment, depth of invasion, lymphatic spread, neoadjuvant therapy exposure, and margin assessment. A platform useful in one setting may not translate uniformly across all GI malignancies. Fourth, implementation must be practical. Intravenous imaging agents, handheld devices, operative timing, fluorescence interpretation, regulatory indications, training, and cost all influence whether a technology can move from innovation showcase to routine care. Finally, the role in advanced endoscopy requires separate evaluation. EMR, ESD, and full-thickness resection operate in different visual and technical environments than open or minimally invasive surgery. The source notes potential future relevance to advanced endoscopic interventions, but does not provide evidence of endoscopic performance. Why this is still worth GastroAGI attention The reason to cover this update is not that it changes clinical practice today. It is worth covering because it illustrates the direction of GI oncology innovation: moving from delayed pathology-dependent feedback toward real-time, biologically informed procedural decision support. This direction aligns with several visible trends in gastroenterology. AGA’s innovation materials highlight AI-fueled endoscopic recording and patient recruitment tools, attachable EUS platforms, unsedated transnasal upper endoscopy, and virtual digestive care models. AGA’s DDW innovation coverage also emphasized AI, genomics, proteomics, workforce development, and systems-level readiness for future GI care. Lumicell fits into this broader narrative as a molecular imaging example. It is neither purely software nor a conventional device. It represents a drug-device imaging platform designed to make cancer biology visible during a procedure. For clinicians and researchers, that is an important conceptual shift. Clinical Takeaway AGA’s “Startup spotlight: Lumicell – illuminating the future of surgical oncology” is a society innovation update, not a GI clinical trial or guideline. It highlights a fluorescence-guided molecular imaging platform that is FDA-approved for breast-conserving surgery and being explored for broader oncology applications, with GI oncology work ongoing. For gastroenterologists, hepatologists, fellows, and GI oncology researchers, the key message is cautious interest. Real-time molecular imaging could eventually support more precise cancer resection and possibly advanced endoscopic therapy, but the current source does not establish GI-specific clinical benefit. The update is useful for awareness, innovation tracking, and research horizon scanning—not for changing current GI cancer management. Five key clinical takeaways Evidence label: Society innovation news / technology spotlight, not a guideline, randomized trial, or GI outcome study. Article verified: AGA published “Startup spotlight: Lumicell – illuminating the future of surgical oncology” on July 20, 2026 . Technology described: Lumicell’s platform uses an intravenously administered protease-activated fluorescent imaging agent with a handheld imaging device to detect fluorescence in the surgical cavity after tumor removal. Current approval context: The AGA source states that the platform is FDA-approved for breast cancer resection, while GI oncology work is ongoing. Clinical interpretation: The GI relevance is promising but unproven; clinicians should not infer improved GI cancer margins, recurrence, survival, or endoscopic outcomes without GI-specific prospective evidence. Source reference and link American Gastroenterological Association. “Startup spotlight: Lumicell – illuminating the future of surgical oncology.” Published July 20, 2026. Source: AGA News.

GastroAGI TeamRead more

10 min readJul 25, 202618reads

Should SNRIs Be Considered the Most Effective Neuromodulators for IBS? A Cautious Reading of the Evidence

In irritable bowel syndrome, clinicians often face a difficult therapeutic question: when symptoms are driven not only by bowel habit but also by pain, visceral hypersensitivity, hypervigilance, and impaired gut–brain regulation, which treatment should be prioritised? Dietary therapy, gut-directed psychological therapy, antispasmodics, laxatives, antidiarrhoeals, secretagogues, antibiotics, and neuromodulators may all have a role depending on phenotype and patient priorities. But the choice of neuromodulator remains particularly nuanced. A recent Gut correspondence brings this debate into focus with the deliberately provocative title: “Should serotonin-noradrenaline reuptake inhibitors be considered the most effective neuromodulators for irritable bowel syndrome?” The article appeared as an online-first letter/correspondence in Gut on the journal’s early online platform under the identifier gutjnl-2026-340002 , with the page dated 21 July 2026 . The correspondence discusses whether serotonin–noradrenaline reuptake inhibitors, or SNRIs , should be considered preferred neuromodulators for IBS based on current evidence. A public author post describes it as correspondence in Gut discussing whether SNRIs should be considered the preferred IBS neuromodulators, with Christian von Mühlenbrock acknowledging Tim Vanuytsel and Jan Tack for mentorship and collaboration. This is not a new randomized trial. It is not a guideline. It is a scholarly response to emerging comparative evidence, especially a recent systematic review and network meta-analysis in Gut evaluating gut–brain neuromodulators and brain–gut behavioural therapies for IBS. That distinction is central: the article should prompt thoughtful interpretation, not immediate rewriting of treatment algorithms. The clinical dilemma: IBS pain is not only a bowel problem IBS is increasingly framed as a disorder of gut–brain interaction. This matters because many patients experience symptoms that are not adequately explained by stool frequency or consistency alone. Abdominal pain, bloating, symptom-related anxiety, central amplification, and altered pain modulation may dominate the clinical picture. Neuromodulators are used in this context not simply as “antidepressants,” but as agents that may influence pain processing, visceral sensitivity, sleep, mood comorbidity, and central modulation of gut symptoms. For gastroenterologists, the terminology matters. Calling these drugs neuromodulators helps separate their GI use from psychiatric labeling and allows more accurate patient counselling. Historically, tricyclic antidepressants have been the most familiar neuromodulator class in IBS practice, particularly when abdominal pain and diarrhoea-predominant symptoms are prominent. Selective serotonin reuptake inhibitors have also been used, often where constipation, anxiety, or mood symptoms coexist. SNRIs sit between these categories conceptually, targeting both serotonin and noradrenaline pathways, with established roles in some chronic pain states outside gastroenterology. The Gut correspondence asks whether the current IBS evidence is strong enough to move SNRIs closer to the front of the neuromodulator discussion. The evidence that triggered the question The correspondence appears to engage with a recent Gut systematic review and network meta-analysis titled “Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis.” That study was published online in Gut in June 2026, with DOI 10.1136/gutjnl-2026-339311 . PubMed indexing confirms the title, journal, DOI, online-ahead-of-print status, and authors including Mais Khasawneh, Elyse R. Thakur, Vivek C. Goodoory, Paul Moayyedi, Christopher J. Black, and Alexander C. Ford. The network meta-analysis compared the relative efficacy of gut–brain neuromodulators and brain–gut behavioural therapies in adults with IBS. It searched the medical literature up to 8 February 2026 for randomized controlled trials. The main analysis used dichotomous endpoints of improvement in either global IBS symptoms or abdominal pain, pooling data using a random-effects model and ranking treatments by P-score. The analysis included 68 eligible RCTs with 6694 participants . Compared with waiting-list control, SNRIs ranked first in six trials involving 387 patients , with a reported relative risk for global IBS symptoms or abdominal pain not improving of 0.49 and a 95% confidence interval of 0.32 to 0.75 . The reported P-score was 0.95 , interpreted as a high probability of ranking as the most efficacious treatment in that network. Tricyclic antidepressants ranked second in 15 trials involving 1519 patients, with a relative risk of 0.60 and 95% confidence interval of 0.43 to 0.85 . Dynamic psychotherapy or emotional processing ranked third, while cognitive behavioural therapy, disease self-management approaches, selective serotonin reuptake inhibitors, and gut-directed hypnotherapy were also reported to be superior to waiting-list control. At first glance, these results make SNRIs look very attractive. But the same abstract also contains the caution that should shape the entire interpretation: no SNRI trials were at low risk of bias , there was possible publication bias in some analyses, and overall certainty of evidence was low or very low for most comparisons. Why “ranked first” does not automatically mean “best first-line choice” Network meta-analysis is useful because it can compare multiple interventions, even when head-to-head trials are limited. However, rankings can be misunderstood. A high P-score does not guarantee that an intervention should become the preferred clinical option. Ranking depends on the available trials, comparator structure, sample size, endpoint definitions, trial quality, and assumptions of comparability across the network. In the Gut network meta-analysis, SNRIs ranked first, but the SNRI evidence came from only six trials and 387 patients. That is a relatively small evidence base compared with many interventions commonly used in IBS. The finding is clinically interesting, but it is not the same as a large, low-bias, pragmatic trial showing superiority of SNRIs over TCAs, CBT, gut-directed hypnotherapy, or standard IBS pharmacotherapy. The comparator also matters. The reported effect was against waiting-list control, not necessarily against an active neuromodulator, structured behavioural therapy, or phenotype-directed medical therapy. Waiting-list controls can exaggerate relative benefit when compared with active placebo or credible therapeutic comparators, particularly in disorders where expectation, therapeutic alliance, and behavioural engagement may influence outcomes. Therefore, the most defensible conclusion is not “SNRIs are the most effective IBS treatment.” It is more precise to say that, in a recent network meta-analysis, SNRIs ranked highly for improvement in global IBS symptoms or abdominal pain, but certainty was limited by trial quality, sample size, and the structure of the evidence. What the correspondence contributes Because the Gut item is a correspondence rather than an original trial, its value lies in interpretation. The title itself frames the central clinical question: should SNRIs be considered the most effective neuromodulators for IBS? That question is important because clinicians may be tempted to translate a ranking result into a prescribing hierarchy. The correspondence appears to challenge or refine that interpretation, asking whether the available evidence justifies calling SNRIs the preferred neuromodulator class. For a GastroAGI audience, this is exactly where the teaching value lies. The correspondence is not practice-changing guidance. It is a prompt to examine how we interpret network meta-analyses in disorders of gut–brain interaction. It reminds clinicians that relative rankings must be weighed against evidence certainty, trial bias, generalisability, tolerability, patient phenotype, comorbidity, and shared decision-making. Practical interpretation for gastroenterologists In clinical practice, neuromodulator selection for IBS is rarely based on a single efficacy estimate. A patient with IBS-D, poor sleep, and pain-predominant symptoms may be approached differently from a patient with IBS-C, prominent anxiety, and medication sensitivity. Another patient may prefer gut-directed hypnotherapy or CBT over pharmacological therapy. A patient already taking an antidepressant for psychiatric indications may require coordination with primary care or psychiatry before any switch or add-on therapy is considered. The Gut network meta-analysis supports the broader concept that several gut–brain interventions can improve IBS symptoms. Its conclusion states that several neuromodulators, especially TCAs, and several brain–gut behavioural therapies, including dynamic psychotherapy or emotional processing, CBT, disease self-management, and gut-directed hypnotherapy, are efficacious for IBS, while also emphasizing low or very low certainty for most comparisons. That broad message may be more clinically useful than the single ranking of SNRIs. IBS management should not become a race to identify one “winner.” Instead, the evidence supports a menu of gut–brain treatments that may be selected according to symptom pattern, patient preference, access, adverse-effect profile, comorbidity, and clinician experience. What clinicians should not infer Clinicians should not infer that SNRIs are now established as first-line neuromodulators for all patients with IBS. The correspondence is a letter, and the underlying network meta-analysis reported limitations in certainty and risk of bias. Clinicians should also avoid interpreting association or comparative ranking as direct causation in routine practice. A network meta-analysis can suggest relative efficacy across trial networks, but it does not prove that an SNRI will outperform a TCA or behavioural therapy for an individual patient in a real-world clinic. Nor should the finding be used to bypass safety considerations. SNRIs have known systemic adverse-effect considerations, including tolerability issues and potential drug interactions, but the accessible Gut correspondence and network meta-analysis abstract do not provide enough detail to make specific safety recommendations here. Any prescribing decision should remain individualized and aligned with local prescribing standards and the patient’s broader medical and psychiatric profile. Why the evidence remains hypothesis-generating The SNRI signal is interesting precisely because it is plausible and clinically relevant. IBS pain may involve altered central pain modulation, and serotonin–noradrenaline pathways are biologically relevant to pain processing. But plausibility does not substitute for high-certainty clinical evidence. The SNRI evidence base in the network meta-analysis was smaller than the TCA evidence base, and the abstract explicitly notes that no trials in the SNRI group were at low risk of bias. That should temper enthusiasm. A highly ranked treatment based on a small number of biased or heterogeneous trials may move down the hierarchy when larger, better-designed trials are completed. Future research should ideally include adequately powered head-to-head comparisons of SNRIs against TCAs, placebo, and credible behavioural interventions. Trials should use standardized IBS outcomes, assess abdominal pain and global symptoms separately, include IBS subtype analyses, report adverse events and discontinuation clearly, and follow patients long enough to understand durability of benefit. A pragmatic trial design would be especially useful. Clinicians need to know not only whether SNRIs work under trial conditions, but which patients tolerate them, which phenotypes benefit most, how they compare with low-dose TCAs in real-world practice, and how they fit alongside dietetic and psychological therapy. A balanced place for SNRIs today The most balanced interpretation is that SNRIs deserve attention as potentially useful gut–brain neuromodulators for IBS, particularly where pain and central modulation are clinically prominent. However, the current evidence does not justify a blanket statement that they are the most effective or universally preferred neuromodulator class. The Gut correspondence is therefore useful not because it provides a new treatment algorithm, but because it sharpens a question that many clinicians already face: how should we integrate emerging comparative evidence into individualized IBS care without over-reading low-certainty rankings? For fellows and trainees, this is a good example of evidence literacy. “Ranked first” is not synonymous with “recommended first.” “Efficacious versus waiting-list control” is not the same as “superior to all active alternatives.” “Neuromodulator” does not mean the same thing as psychiatric treatment. And “promising” does not mean practice-changing. Clinical Takeaway The Gut correspondence “Should serotonin-noradrenaline reuptake inhibitors be considered the most effective neuromodulators for irritable bowel syndrome?” is best read as an interpretive caution around a provocative signal from a recent network meta-analysis. SNRIs ranked highly in that analysis, but the evidence came from a small number of trials, none at low risk of bias, and the overall certainty of evidence for most comparisons was low or very low. For clinicians, SNRIs should be considered an important area for further study and a possible option within individualized IBS neuromodulator practice. They should not yet be presented as the established most effective neuromodulator for all IBS patients. The evidence is hypothesis-generating and clinically relevant , but not practice-changing on its own. Five key clinical takeaways The selected Gut article is a letter/correspondence , not a randomized trial, guideline, or original cohort study. The correspondence asks whether SNRIs should be considered the most effective IBS neuromodulators , reflecting debate after a recent network meta-analysis. The underlying Gut network meta-analysis included 68 RCTs and 6694 participants evaluating gut–brain neuromodulators and brain–gut behavioural therapies in adults with IBS. SNRIs ranked first in that analysis , but the SNRI evidence came from six trials with 387 patients, and no SNRI trials were judged at low risk of bias. The appropriate clinical message is caution : SNRIs are promising but should not yet be treated as established first-choice neuromodulators for all IBS patients. Source reference and link Von Mühlenbrock C, Vanuytsel T, Tack J. “Should serotonin-noradrenaline reuptake inhibitors be considered the most effective neuromodulators for irritable bowel syndrome?” Gut . Online first, 21 July 2026. Article identifier: gutjnl-2026-340002. Context source: Khasawneh M, Thakur ER, Goodoory VC, Moayyedi P, Black CJ, Ford AC. “Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis.” Gut . Online ahead of print, June 2026. DOI: 10.1136/gutjnl-2026-339311.

GastroAGI TeamRead more

11 min readJul 25, 20260reads

Risk-Based Pathology Reporting After ESD for Early GI Cancer: New International Consensus Standards

After endoscopic submucosal dissection for early gastrointestinal cancer, the endoscopy report tells only part of the story. The resection may appear technically successful, the lesion may have been removed en bloc, and the patient may leave the unit believing that definitive treatment has been completed. But the next major clinical decision often depends on the pathology report: was this resection curative, or does the patient need further treatment? That answer is rarely based on one histological feature alone. It depends on a risk-based synthesis of invasion depth, invasion breadth, margin status, lymphovascular invasion, tumour budding, differentiation, histological subtype, perineural invasion, specimen handling, and the reliability of the measurements reported. When these elements are reported inconsistently, multidisciplinary teams may struggle to determine whether surveillance is appropriate or whether additional therapy should be considered. A new international consensus article in Gut , titled “Risk-based pathology reporting after endoscopic submucosal dissection for early gastrointestinal cancer: international consensus standards,” addresses this exact problem. The article was published online ahead of print on 10 July 2026 and carries the DOI 10.1136/gutjnl-2025-337567 . The work was led by Kareem Khalaf and colleagues and developed through an international modified Delphi consensus process. The pathology report as the second half of ESD Endoscopic submucosal dissection, or ESD, enables en bloc resection of selected early gastrointestinal cancers. Its clinical value is not limited to removal of the lesion. By preserving the specimen in a more intact form than piecemeal resection, ESD allows detailed pathological assessment of features that may influence residual disease risk, lymph node metastasis risk, and the need for additional treatment. The consensus paper identifies a key limitation in current practice: pathology reporting remains variable for several parameters that determine whether a resection is considered curative and whether further therapy should be discussed. These include submucosal invasion depth and breadth, margin status, lymphovascular invasion, tumour budding, differentiation, and the use of ancillary stains. For clinicians, this variability is not merely administrative. A pathology report that describes invasion imprecisely, omits adverse histological features, or uses unclear margin terminology may alter how the case is interpreted in an MDT meeting. The same technically successful ESD could be considered low-risk in one setting and indeterminate in another, depending not on tumour biology but on reporting conventions. This consensus article is therefore clinically relevant because it focuses on the interface between endoscopy, pathology, surgery, oncology, and surveillance planning. It is not a trial of ESD technique and not a study of a new device or drug. It is a standards document intended to make pathology reporting after ESD more reproducible and clinically meaningful. What the consensus process actually studied The objective was to develop practical international standards for the pathology assessment and reporting of invasive carcinoma in ESD specimens. The study design was an international modified Delphi consensus process . The panel included 42 experts from 15 countries , comprising 28 gastrointestinal pathologists and 14 therapeutic endoscopists . That composition matters. Post-ESD decision-making sits at the junction of pathology interpretation and therapeutic endoscopy. Pathologists define the histological risk features; endoscopists and MDTs use those features to guide surveillance, further endoscopic treatment, surgical referral, or oncological discussion. A reporting standard developed by both groups is more likely to address real-world clinical decision points. The consensus statements covered measurement of invasion, margin assessment, staining, specimen handling, prognostic histological features, and clinically relevant reporting. In total, 56 recommendations reached consensus across seven domains . The population should be understood correctly. This was not a patient cohort study. There was no intervention group, control group, survival endpoint, recurrence endpoint, or colectomy endpoint. The “population” in methodological terms was the expert panel. The clinical material under consideration was ESD specimens containing invasive carcinoma from early gastrointestinal cancer. The outcome was expert consensus on reporting standards, not proof that these standards improve patient outcomes. That distinction is central. The paper may influence practice by standardising the information that clinicians use, but it does not establish causation between standardised reporting and improved survival, reduced recurrence, or reduced surgery. Submucosal invasion: measuring what clinicians need to know One of the most clinically important areas addressed is submucosal invasion. In early gastrointestinal cancers treated by ESD, the depth of invasion into the submucosa is a key element in risk assessment. The consensus panel recommends using the Sm1–Sm3 subclassification only when the muscularis propria is present . When the muscularis propria is absent, submucosal invasion depth should be reported in micrometres , rounded to the nearest 100 µm . This is a practical recommendation. A classification system that depends on a histological landmark cannot be applied reliably when that landmark is absent. Reporting invasion depth in micrometres provides a more explicit measurement and reduces ambiguity. The panel also recommends reporting submucosal invasion breadth in millimetres as an adjunct metric for future validation. This should not be overinterpreted. The accessible source does not state that invasion breadth is already a validated standalone determinant of management. Rather, the consensus supports reporting it so that future studies can evaluate its prognostic value more consistently. For clinicians, the immediate implication is that pathology reports should be detailed enough to support risk assessment and future evidence development. Margin terminology: removing ambiguity from a high-stakes variable Margin status is another central domain. The panel recommends that margin positivity should be defined as direct tumour contact with the inked surface . This assessment should be supported by standardised pinning, inking, complete embedding, and parallel sectioning. This matters because terms such as “positive,” “close,” “involved,” “clear,” and “indeterminate” can be used inconsistently. In the post-ESD setting, margin status may influence whether a resection is considered complete and whether the patient is discussed for repeat endoscopic therapy, surgery, or close surveillance. The consensus also links margin interpretation to specimen handling. This is important because the quality of the final pathology report depends on what happens before the slide is read. Pinning, inking, embedding, and sectioning are not technical afterthoughts. They determine whether a pathologist can confidently assess the relationship between tumour and resection surface. For endoscopists, this reinforces the need for close communication with pathology teams. A high-quality ESD specimen can still produce a less useful report if orientation and processing are inconsistent. Conversely, standardised pathology workflows can increase the clinical value of an en bloc resection. Ancillary stains: targeted use rather than routine escalation The consensus retains H&E as the baseline stain . Selective immunohistochemistry or elastic stains are recommended for specific scenarios, including equivocal lymphovascular invasion, distorted architecture, or difficult margin interpretation. This is a balanced approach. It avoids implying that every ESD specimen requires extensive ancillary staining. At the same time, it recognises that some clinically important features may be difficult to assess on routine staining alone. Lymphovascular invasion is particularly relevant because it contributes to post-resection risk assessment. The consensus does not say that ancillary stains should replace standard histology. Instead, it supports selective use when interpretation is uncertain. For clinicians reviewing pathology reports, the nuance is important. The absence of ancillary stains does not automatically mean inadequate assessment. But when lymphovascular invasion or margin interpretation is equivocal, selective stains may improve diagnostic confidence. Tumour budding and composite risk: moving beyond isolated descriptors The panel recommends that tumour budding should be reported according to International Tumour Budding Consensus Conference criteria . It also states that differentiation, histological subtype, lymphovascular invasion, perineural invasion, and margin status should be integrated into composite risk assessment. This is perhaps the most important conceptual point. Pathology after ESD should not be a disconnected list of microscopic observations. It should support clinically relevant risk assessment. Composite risk does not mean inventing an unvalidated score. It means recognising that individual features interact in clinical decision-making. A lesion with shallow invasion but lymphovascular invasion may raise different concerns from a lesion with a clear margin and no adverse features. Similarly, tumour differentiation, histological subtype, perineural invasion, and margin status may affect how confidently the MDT can call a resection curative. The consensus standards are described as synoptic-ready , meaning they can be incorporated into structured reporting formats. Synoptic reporting may be especially valuable in MDT settings because it reduces omissions, standardises terminology, and allows future aggregation of data for quality improvement and research. Why this matters for multidisciplinary care The conclusion of the article states that the standards provide immediately implementable, synoptic-ready pathology reporting criteria after ESD. By standardising measurement landmarks, margin terminology, ancillary stain use, and reporting of adverse histological features, the authors aim to reduce interinstitutional variability, improve multidisciplinary decision-making, and support future validation of risk models in early gastrointestinal cancer. That conclusion is highly relevant to GI cancer MDTs. After ESD, the clinical question is often not simply whether the lesion was removed. The question is whether the histological profile supports surveillance alone or whether the patient should be considered for additional treatment. Some cases are straightforward. Others are not. A close or uncertain margin, borderline invasion depth, equivocal lymphovascular invasion, adverse differentiation, or tumour budding can create uncertainty. Standardised reporting does not eliminate clinical judgment, but it improves the quality of the information on which clinical judgment is based. For fellows and trainees, this paper is also a useful reminder that pathology reports are not passive documents. They are clinical tools. The way invasion, margins, and adverse histological features are measured and reported can shape real patient management. What clinicians can conclude Clinicians can conclude that an international expert panel reached consensus on 56 recommendations for pathology assessment and reporting after ESD for early gastrointestinal cancer. These recommendations address invasion measurement, margin definition, staining, specimen handling, prognostic histological features, and clinically relevant reporting. Clinicians can also conclude that the paper supports a more structured, risk-based, synoptic-ready approach to pathology reporting after ESD. This is especially relevant where endoscopic resection is being used for early invasive carcinoma and post-resection decisions depend heavily on histological risk features. However, clinicians should not conclude that this article proves improved survival, lower recurrence, reduced lymph node metastasis, or reduced need for surgery. The accessible source does not report patient outcomes after implementation of these standards. It also does not validate a new risk model. Instead, it provides consensus-based criteria designed to improve reporting consistency and support future validation. What remains uncertain Several important questions remain. First, implementation may vary by pathology resources. Standardised pinning, inking, complete embedding, parallel sectioning, and selective ancillary staining require coordinated workflows. Institutions with high ESD volume may be able to adopt these standards more easily than lower-volume centres. Second, the clinical effect of implementation still needs study. Future research should evaluate whether structured, risk-based reports reduce reporting variability, improve agreement in MDT recommendations, reduce unnecessary additional treatment, identify patients needing escalation more accurately, or improve long-term outcomes. Third, submucosal invasion breadth remains an adjunct metric for future validation in the accessible abstract. It should be reported, but the source does not establish it as an independent treatment threshold. Fourth, early gastrointestinal cancers across different organs may require site-specific interpretation. Esophageal, gastric, colorectal, and other GI cancers do not all carry identical risk frameworks. The consensus provides common pathology reporting standards, but clinical application should still be integrated with tumour site, patient factors, local expertise, and established care pathways. Clinical Takeaway The new Gut international consensus standards mark an important step toward more consistent, clinically actionable pathology reporting after ESD for early gastrointestinal cancer. The central message is not that pathology should become more complex. It is that the clinically decisive elements should be measured, defined, and reported in a standardised way. For gastroenterologists and therapeutic endoscopists, the post-ESD pathology report should answer more than whether cancer was present. It should help determine whether resection was likely curative, whether adverse histological features are present, whether margins are truly positive, and whether the case requires further multidisciplinary discussion. This is consensus-based guidance, not outcome-proven evidence of improved survival or recurrence reduction. Its immediate value lies in standardisation. Its future value will depend on whether these reporting standards improve risk prediction, reduce interinstitutional variability, and support better patient-level decisions after endoscopic resection. Five key clinical takeaways The article is “Risk-based pathology reporting after endoscopic submucosal dissection for early gastrointestinal cancer: international consensus standards,” published online in Gut on 10 July 2026 . The study design was an international modified Delphi consensus process , not a patient outcome study. The panel included 42 experts from 15 countries , including 28 gastrointestinal pathologists and 14 therapeutic endoscopists . The consensus produced 56 recommendations across seven domains , including invasion measurement, margin assessment, staining, specimen handling, prognostic histological features, and clinically relevant reporting. These standards are intended to reduce reporting variability and improve MDT decision-making, but they do not prove improved survival, recurrence reduction, or reduced need for surgery. Source reference and link Khalaf K, Li H, Iwaya M, Orr CE, Schneider M, Iwaya Y, Yuan Y, Saito Y, Shimamura Y, Messmann H, Jacques J, Hassan C, Repici A, von Renteln D, Pellisé M, Elkholy S, Anderson JT, Cai M, Pouw RE, Yang D, Chiu PWY, Lauwers GY, Kumarasinghe MP, Ushiku T, Streutker CJ, Wang T, Hurlbut D, Grin A, Bellizzi A, Kim KM, Charissoux A, Fenouil T, Terris B, de Hertogh G, Jansen M, Meijer SL, Vieth M, Nakanishi Y, Kawachi H, Xu C, Abd El-Kareem D, Ohashi K, Brown I, Kirsch R, Singh C, Knight K, Montgomery EA, Cuatrecasas M, Saez de Gordoa K, Bechara R. Risk-based pathology reporting after endoscopic submucosal dissection for early gastrointestinal cancer: international consensus standards. Gut . Published online 10 July 2026. DOI: 10.1136/gutjnl-2025-337567 .

GastroAGI TeamRead more

10 min readJul 25, 202622reads

New Diagnostic Criteria for Acute Severe Ulcerative Colitis: REFINED-ASUC Consensus for the Modern Treatment Era

Acute severe ulcerative colitis remains one of the highest-stakes scenarios in inflammatory bowel disease care. The first clinical question is deceptively simple: does this patient meet criteria for ASUC? The answer can determine admission urgency, inpatient monitoring intensity, timing of intravenous corticosteroids, need for rescue therapy discussions, endoscopic evaluation, infection assessment, radiology, and early surgical involvement. For decades, that decision has usually been anchored to the 1955 Truelove and Witts criteria . The problem is not that those criteria are irrelevant; it is that the therapeutic landscape around ulcerative colitis has changed dramatically. Many patients now present after outpatient exposure to corticosteroids, biologics, or small-molecule advanced therapies. A modern patient may arrive already partially treated, with attenuated fever, altered inflammatory markers, or a symptom pattern that does not map neatly onto older definitions. The new article “New Diagnostic Criteria for Acute Severe Ulcerative Colitis in the Modern Treatment Era: A Modified Delphi Consensus by REFINED-ASUC” directly addresses this gap. Published online in Clinical Gastroenterology and Hepatology on July 22, 2026 , the paper reports a four-round modified Delphi process and consensus meeting involving European, North American, and Asia-Pacific gastroenterologists. The working group was named REFINED-ASUC , standing for Refined Evaluation Framework and Investigations for Diagnostics in ASUC . Why older ASUC definitions need refinement The article begins from a clinically familiar premise: ASUC is a potentially life-threatening manifestation of ulcerative colitis, and its diagnosis has typically relied on the Truelove and Witts criteria. However, those historic criteria do not incorporate prior or current treatment with corticosteroids or modern advanced therapies. That omission matters because outpatient treatment can modify the phenotype seen at presentation. A patient already receiving corticosteroids may have a different inflammatory signal than an untreated patient. A patient receiving advanced therapy may still have clinically severe disease, but the pattern of symptoms and laboratory abnormalities may not behave exactly as expected from older cohorts. The REFINED-ASUC consensus therefore does not simply ask whether older criteria are “right” or “wrong.” It asks whether clinicians need a more contemporary diagnostic framework that acknowledges the treatment context in which ASUC now presents. What the REFINED-ASUC group investigated This was not a randomized trial, cohort study, or validation study. It was a modified Delphi consensus designed to gather expert opinion on potential criteria and diagnostic approaches for ASUC in contemporary practice, including patients already receiving outpatient corticosteroids or advanced therapy. The Delphi panel included gastroenterologists from Europe, North America, and the Asia-Pacific region. The process involved four Delphi rounds and a consensus meeting. Consensus was defined as at least 70% agreement or disagreement for Likert-scale statements, or at least 70% homogeneity for single-choice or multiple-choice responses. This design is important for interpretation. Delphi methodology is useful when clinical practice faces a definitional gap and randomized evidence is unavailable or impractical. It can produce structured expert agreement, but it does not prove that the proposed criteria predict outcomes better than existing criteria. REFINED-ASUC should therefore be understood as a consensus framework requiring prospective validation, not as a completed diagnostic performance study. The proposed structure: major and minor criteria The most clinically actionable output is the proposed diagnostic structure for patients already treated with advanced therapy or corticosteroids. The panel reached consensus that ASUC diagnosis in this group could be based around three major criteria plus at least two minor criteria . The major criteria were: C-reactive protein at least two times the upper limit of normal, six or more bowel movements per 24 hours, and visible blood in at least 50% of bowel movements over 24 hours . The minor criteria included low albumin, increased heart rate, nocturnal bowel movements, low hemoglobin, increased body temperature, or elevated leukocyte count . This approach is clinically intuitive. It retains the central role of stool frequency and bleeding, but it also incorporates systemic inflammation, nutritional or inflammatory burden through albumin, anemia, nocturnal symptoms, heart rate, temperature, and leukocyte count. Instead of relying on a single historical threshold, it creates a composite diagnostic picture. For gastroenterologists, the key practical message is that ASUC assessment may need to become more explicitly multidimensional, especially in patients whose outpatient therapy has already modified their presentation. High-dose corticosteroids: a distinct subgroup One of the most important details in the abstract is that patients already receiving high-dose corticosteroids were considered a subgroup requiring different thresholds. For these patients, consensus thresholds included CRP at least one times the upper limit of normal and visible blood in at least 33% of bowel movements over 24 hours , rather than the higher inflammatory and bleeding thresholds used in the broader treated group. This is a clinically meaningful distinction. It reflects the possibility that high-dose steroids may suppress or alter some markers of disease severity without eliminating risk. A patient on high-dose corticosteroids may still have severe colitis even if CRP or bleeding proportion does not meet stricter thresholds. However, this should be framed carefully. The consensus suggests different diagnostic thresholds for this subgroup, but the source does not establish that these thresholds have been prospectively validated against outcomes such as colectomy, rescue therapy failure, complications, or mortality. The appropriate conclusion is that high-dose steroid exposure should influence diagnostic interpretation—not that the proposed cutoffs are already proven superior in all settings. Untreated patients: similar principles, less consensus The abstract reports that similar principles were agreed for untreated patients, but without achieving consensus . That caveat is important. It means the strongest consensus output applies to patients already receiving outpatient corticosteroids or advanced therapy. For untreated patients, the direction of thinking may be similar, but the Delphi process did not reach the same level of formal agreement. Clinicians should therefore avoid overextending the framework. REFINED-ASUC is most clearly positioned as a modern diagnostic approach for already-treated patients, where the traditional criteria may be least well adapted. Endoscopy and radiology remain part of the diagnostic pathway The REFINED-ASUC panel also agreed that endoscopy should be used to confirm ASUC diagnosis and to exclude cytomegalovirus infection. The panel further agreed that radiologic investigations should support exclusion of toxic megacolon. This point deserves emphasis because diagnostic criteria should not be interpreted as replacing clinical investigation. In ASUC, symptom and laboratory criteria are part of the evaluation, but they do not remove the need to assess for alternative or complicating diagnoses. Cytomegalovirus infection can influence management, and toxic megacolon is a critical complication that must not be missed. The source does not specify a detailed endoscopic protocol, imaging modality, or timing sequence in the abstract. Therefore, any practical implementation should remain aligned with local ASUC pathways and existing institutional practice until the full consensus document is integrated into guidelines or validated pathways. How this may affect clinical thinking The immediate impact of REFINED-ASUC is conceptual and operational. It encourages clinicians to ask, at the point of assessment: what treatment has the patient already received, and how might that change the diagnostic threshold for severe disease? This is particularly relevant in contemporary IBD care, where patients may present to hospital after outpatient corticosteroids, biologics, Janus kinase inhibitors, sphingosine-1-phosphate receptor modulators, or other advanced therapies. The abstract specifically refers to outpatient treatment with corticosteroids and advanced therapy, rather than naming each therapeutic class. The proposed criteria may also help standardize communication across emergency departments, inpatient teams, IBD specialists, and surgeons. A structured major/minor framework could make it easier to document why a patient is being treated as ASUC despite prior therapy or partially modified inflammatory markers. For clinical research, the implications may be even greater. Trial eligibility, cohort definitions, and comparisons across studies depend on consistent disease definitions. If validated, a modern treatment-aware ASUC definition could improve study design and make research populations more representative of current practice. What clinicians should not conclude The most important restraint is that this is consensus , not outcome validation. The authors themselves conclude that the criteria include additional clinical and laboratory parameters for validation in prospective studies . Therefore, clinicians should not conclude that the REFINED-ASUC criteria have already been proven to outperform Truelove and Witts criteria in predicting colectomy, steroid failure, rescue therapy requirement, mortality, or length of stay. The abstract does not provide sensitivity, specificity, predictive values, calibration, or comparative prognostic performance. Clinicians also should not treat the criteria as a substitute for clinical judgment. A patient with suspected severe colitis, systemic toxicity, rapid deterioration, profound anemia, hypoalbuminemia, infection concern, or radiologic complication may require urgent management even when a formal threshold is uncertain. Conversely, criteria-based labeling should be integrated with endoscopic, infectious, radiologic, and multidisciplinary assessment. Finally, this consensus does not by itself define treatment sequencing. It addresses diagnosis and diagnostic approach, not comparative treatment recommendations for intravenous corticosteroids, rescue therapy, surgery, or advanced therapy selection. Strengths of the consensus The main strength is that the REFINED-ASUC process addresses a real and increasingly common clinical problem: ASUC definitions developed before modern therapy may not fit patients already treated before hospital presentation. The panel was geographically broad, including European, North American, and Asia-Pacific gastroenterologists, which supports relevance beyond a single national practice environment. The four-round Delphi process and predefined consensus threshold add methodological structure. Another strength is the explicit incorporation of both clinical and laboratory parameters. The proposed framework recognizes that ASUC is not defined by stool frequency alone. Bleeding burden, inflammatory markers, albumin, hemoglobin, fever, leukocytosis, heart rate, and nocturnal bowel movements may all contribute to the severity signal. The inclusion of endoscopy, cytomegalovirus exclusion, and radiologic assessment for toxic megacolon also keeps the framework grounded in the realities of inpatient severe colitis evaluation. Limitations and uncertainty The limitations are equally central to interpretation. Delphi consensus depends on expert agreement. It can identify what experienced clinicians believe is reasonable, but it cannot determine diagnostic accuracy without subsequent empirical testing. The abstract does not report patient-level validation, outcome prediction, comparison against established criteria, or performance across different healthcare systems. It also does not establish how the proposed thresholds perform in special populations, such as older patients, pregnant patients, patients with comorbid infection, or patients receiving specific classes of advanced therapy. Another uncertainty is implementation. A major/minor criteria framework may be easy to describe, but it requires reliable 24-hour stool counts, accurate recording of visible blood proportion, laboratory standardization around upper limits of normal, and timely availability of endoscopy and radiology. These may vary across inpatient settings. Most importantly, prospective validation is needed before the criteria can be considered practice-changing. The authors explicitly state that the additional clinical and laboratory parameters require validation in prospective studies. Where REFINED-ASUC may fit next The most logical next step is prospective evaluation in hospitalized ulcerative colitis cohorts. Future studies should test whether the proposed criteria identify patients at risk for clinically meaningful outcomes, including steroid nonresponse, need for rescue therapy, colectomy, toxic megacolon, intensive care, readmission, and mortality. It would also be useful to compare REFINED-ASUC criteria directly with traditional Truelove and Witts criteria, particularly in patients already receiving corticosteroids or advanced therapy. Subgroup analyses by treatment exposure, corticosteroid dose, disease extent, biomarker profile, and endoscopic severity would clarify where the new criteria add the most value. For now, REFINED-ASUC is best viewed as a structured consensus proposal that reflects how modern IBD experts are thinking about ASUC diagnosis in treated patients. It is not yet a fully validated replacement for existing definitions. Clinical Takeaway REFINED-ASUC proposes a modern, treatment-aware diagnostic framework for acute severe ulcerative colitis. The consensus recognizes that patients already receiving corticosteroids or advanced therapy may not fit older ASUC definitions developed in a different therapeutic era. The proposed approach combines major criteria—CRP, bowel movement frequency, and visible blood—with minor clinical and laboratory features, while emphasizing endoscopic confirmation, cytomegalovirus exclusion, and radiologic assessment for toxic megacolon. For clinicians, the message is practical but cautious: treatment history should influence how ASUC is diagnosed , especially in patients already exposed to outpatient therapy. The criteria are clinically relevant and likely to shape future research, but they require prospective validation before being treated as definitive or practice-changing guidance. Five key clinical takeaways REFINED-ASUC is a modified Delphi consensus , not a randomized trial or validated diagnostic performance study. The article was published online in Clinical Gastroenterology and Hepatology on July 22, 2026 , with Tim Raine and colleagues as authors. The consensus focuses on modern ASUC diagnosis , especially in patients already receiving outpatient corticosteroids or advanced therapy. Proposed criteria include three major features plus at least two minor features in treated patients, with different thresholds suggested for those on high-dose corticosteroids. The criteria are not yet practice-changing on their own ; the authors state that prospective validation is needed. Source reference and link Raine T, Peyrin-Biroulet L, Begun J, Biedermann L, Blumenstein I, Cheifetz AS, Colombel JF, Dulai PS, Gecse KB, Jairath V, Nakase H, Panaccione R, Reinisch W, Verstockt B, Higgins PDR. “New Diagnostic Criteria for Acute Severe Ulcerative Colitis in the Modern Treatment Era: A Modified Delphi Consensus by REFINED-ASUC.” Clinical Gastroenterology and Hepatology . Published online July 22, 2026. DOI: 10.1016/j.cgh.2026.07.011 .

GastroAGI TeamRead more

9 min readJul 24, 202623reads

Singing Therapy for Supragastric Belching: A Randomized Trial Challenges Conventional Breathing Therapy

For patients with supragastric belching, the consultation often begins with frustration. The symptom is visible, socially disruptive, and frequently misunderstood. Many patients have already tried acid suppression, dietary changes, reassurance, or repeated investigations before the mechanism is recognized as behavioral rather than gastric. Once supragastric belching is identified, clinicians commonly turn to behavioral strategies such as diaphragmatic breathing, speech therapy, or other brain–gut behavioral approaches. Yet a practical challenge remains: can patients engage with these techniques consistently enough for them to work? A new multicenter randomized controlled trial published in Clinical Gastroenterology and Hepatology asks an unusual but clinically relevant question: could structured singing therapy outperform conventional diaphragmatic breathing for supragastric belching? The article, titled “Singing Therapy versus Diaphragmatic Breathing for Supragastric Belching: A Multicenter Randomized Controlled Trial,” studied 72 patients with supragastric belching diagnosed using Rome IV criteria and compared a one-week structured singing program with diaphragmatic breathing exercises. The result is not a reason to replace established care overnight. But it is a reason for gastroenterologists to pay attention. A behavioral disorder where treatment adherence matters Supragastric belching differs from physiological gastric belching. In supragastric belching, air rapidly enters and exits the esophagus without reaching the stomach. This makes it a behavioral esophageal disorder rather than a simple excess-gas problem. The clinical implication is important: therapies aimed only at acid suppression, gas reduction, or dietary manipulation may not address the mechanism driving symptoms. The AGA news report accompanying the trial describes diaphragmatic breathing as the guideline-recommended first-line behavioral treatment for supragastric belching. However, the same report notes that some patients find breathing exercises repetitive and difficult to sustain. That practical barrier appears to be part of the rationale for testing singing therapy, which also involves controlled diaphragmatic breathing but may feel more engaging and familiar to patients. This is where the study’s clinical appeal lies. The intervention is not pharmacologic, invasive, or technologically complex. It attempts to repackage respiratory and abdominal control into a form that may be easier for patients to practice. What the trial investigated The study was a multicenter randomized controlled trial conducted at two tertiary gastroenterology centers in China between October 2024 and April 2025 . Investigators screened 92 patients with supragastric belching and randomly assigned 72 patients in a 1:1 ratio to either structured singing therapy or diaphragmatic breathing for one week. Four patients in each group withdrew during the intervention, leaving 32 patients per group who completed treatment and 30 per group who completed one-month follow-up. Patients were diagnosed according to Rome IV criteria . Baseline demographic characteristics, belching symptom severity, gastrointestinal symptom scores, quality-of-life measures, anxiety scores, and depression scores were reported as similar between groups. The primary outcome was treatment response, defined as at least a 50% reduction in belching visual analog scale scores . Secondary outcomes included health-related quality of life, gastrointestinal symptom severity, anxiety, depression, and treatment acceptability. Outcomes were assessed at baseline, immediately after the one-week intervention, and again at one month. What singing therapy actually involved The singing intervention was structured rather than casual. Participants performed five-minute sessions three times daily for one week , with additional sessions during belching episodes. They sang one of four standardized Chinese folk songs while focusing on diaphragmatic breathing, sustained vocalization, abdominal movement, and visual and tactile feedback. The comparator group received individualized instruction from a gastroenterologist and practiced five-minute diaphragmatic breathing exercises three times daily, with additional sessions when symptoms occurred. This distinction matters. The study did not compare singing with no treatment, nor did it compare singing with vague breathing advice. It compared two active behavioral approaches over the same short treatment duration. That strengthens the clinical relevance of the finding, although it does not eliminate important limitations. The main finding: stronger short-term response with singing After one week, the response rate was higher with singing therapy than with diaphragmatic breathing. In the AGA report, 72% of patients assigned to structured singing met the response threshold at one week compared with 39% assigned to diaphragmatic breathing. At one month, the separation persisted: 50% of patients in the singing group still met response criteria compared with 31% in the diaphragmatic breathing group. The journal abstract reports similar results using precise trial figures: 72.2% vs 38.9% immediately after intervention, with P = .004 , and 50.0% vs 30.6% at one-month follow-up, with P = .032 . The per-protocol analysis followed the same direction, with response rates of 81% for singing therapy versus 44% for diaphragmatic breathing. Belching symptoms improved in both groups, but the singing group had greater symptom reduction immediately after treatment, and the benefit in belching relief was maintained at follow-up. This is clinically meaningful because diaphragmatic breathing is already used in practice. The trial does not merely show that singing can help compared with doing nothing. It suggests that a more engaging respiratory-vocal exercise may produce greater short-term improvement than a familiar behavioral comparator. Quality of life and acceptability: the implementation signal Symptom response is important, but behavioral therapies succeed or fail partly on acceptability. The trial found that quality of life improved more with singing therapy immediately after treatment. Specifically, EuroQol visual analog scale scores increased more with singing than with diaphragmatic breathing at treatment completion. Scores declined somewhat in both groups by one month but remained higher than baseline. Other secondary outcomes, including gastrointestinal symptom severity, anxiety, and depression, improved in both groups without a broad advantage for singing. Depression scores differed at one month, but investigators considered this unlikely to be clinically meaningful because patients with severe anxiety or depression had been excluded. Treatment acceptability may be one of the most interesting signals. Responders rated the intervention as more acceptable than nonresponders, and patients assigned to singing therapy rated treatment acceptability higher than those assigned to diaphragmatic breathing. Higher acceptability was associated with greater improvement in belching symptoms. This does not prove that acceptability caused better outcomes. Patients who improve may naturally rate an intervention more favorably. Still, the association is clinically plausible and relevant. If a patient finds a behavioral exercise engaging, they may practice it more consistently, especially when symptoms occur. Which patients might benefit most? The trial’s multivariable analysis identified three independent predictors of treatment response: assignment to singing therapy, older age, and greater baseline belching severity. Patients assigned to singing therapy were reported to be nearly seven times more likely to achieve treatment response than those assigned to diaphragmatic breathing. Sex, body mass index, gastrointestinal symptom severity, quality-of-life scores, anxiety, and depression were not associated with treatment response. This should be interpreted cautiously. The investigator commentary emphasized that age and baseline severity findings came from an exploratory predictor analysis rather than a prespecified subgroup comparison. Clinicians should therefore not use age or severity as strict eligibility criteria for singing therapy. A practical interpretation is narrower: older patients and those with more severe symptoms may be promising candidates for future research, and possibly for clinical experimentation where behavioral therapy is already being used. But the evidence is not strong enough to define a treatment-selection rule. What clinicians should conclude now The trial supports the view that structured singing therapy is a credible behavioral intervention for supragastric belching, at least in the short term and in the studied population. It was superior to diaphragmatic breathing for the primary response outcome after one week, and the difference remained statistically significant at one month. What clinicians should not conclude is equally important. This study does not establish singing therapy as a universal first-line standard. Follow-up was limited to one month. Blinding was not possible because the interventions were behavioral. Adherence was self-reported. The symptom visual analog scale used to assess belching symptoms was not formally validated. Diagnosis was based on clinical history and observation rather than high-resolution esophageal manometry or pH-impedance testing, which means diagnostic misclassification cannot be fully excluded. Generalizability is another issue. The study was conducted in Chinese tertiary centers, and the intervention used culturally familiar Chinese folk songs. It is plausible that structured singing could be adapted across cultures, but the evidence does not yet prove that any song, language, delivery method, or patient population will produce the same results. How this may influence practice For now, singing therapy is best viewed as an early but clinically interesting behavioral option , not a practice-changing mandate. It may be especially relevant for patients who understand the behavioral mechanism of supragastric belching but struggle to practice standard diaphragmatic breathing consistently. In a clinical setting, the study may encourage gastroenterologists to think more creatively about behavioral retraining. The mechanism being targeted is not the song itself, but coordinated diaphragmatic, abdominal, respiratory, and glottal control. Singing may offer a structured, memorable way to practice those elements. This could also strengthen collaboration between gastroenterologists, speech-language therapists, psychologists, and motility specialists. A standardized protocol, culturally adaptable song selection, training materials, adherence monitoring, and objective physiologic confirmation would be needed before broader implementation. The most responsible message for patients is not “singing cures belching.” It is that a small randomized trial suggests structured singing exercises may reduce supragastric belching more than conventional diaphragmatic breathing over short-term follow-up, but longer and more diverse studies are needed. Remaining evidence gaps Several questions remain unanswered. Would the benefit persist at three, six, or twelve months? Would longer treatment produce stronger or more durable results? Would patients with pH-impedance-confirmed supragastric belching respond similarly? Can the intervention be delivered by gastroenterologists, speech therapists, digital tools, or group sessions? How much practice is necessary, and what predicts adherence? The trial authors are reportedly preparing follow-up work to assess whether patients benefit from extending the treatment course and from longer follow-up. Those next studies matter because supragastric belching is often chronic and relapse-prone. A one-week response is encouraging, but durable behavioral retraining is the real clinical endpoint. Clinical Takeaway Structured singing therapy is an intriguing, low-risk behavioral intervention for supragastric belching. In a multicenter randomized trial of 72 patients, it produced higher short-term response rates than diaphragmatic breathing, with benefits persisting at one month. The study is clinically relevant because it tests an active, engaging alternative to standard breathing exercises. However, the evidence remains early: follow-up was short, diagnosis was not physiologically confirmed in all patients, the symptom scale was not formally validated, and cultural adaptation is uncertain. For gastroenterologists, the study should expand the conversation around behavioral therapy for supragastric belching. It should not yet rewrite treatment algorithms. Five key clinical takeaways Study design: Multicenter randomized controlled trial comparing structured singing therapy with diaphragmatic breathing in 72 patients with Rome IV–defined supragastric belching. Primary outcome: Singing therapy achieved higher treatment response, defined as at least 50% reduction in belching visual analog scale score, at one week and one month. Clinical relevance: Singing may improve engagement with respiratory-abdominal retraining, a major practical barrier in behavioral treatment. Limitations: Short follow-up, lack of blinding, self-reported adherence, nonvalidated belching VAS, and absence of routine physiologic confirmation limit certainty. Practice signal: Early but interesting; reasonable to view as an alternative or complementary behavioral strategy, not established guideline-changing therapy. Source reference and link Shang H, Ma H, Xu Z, Gao Y, Bai T, Hou X. “Singing Therapy versus Diaphragmatic Breathing for Supragastric Belching: A Multicenter Randomized Controlled Trial.” Clinical Gastroenterology and Hepatology , published online July 2026. Additional source: AGA / GI & Hepatology News report, “Singing therapy outperformed breathing exercises in supragastric belching trial,” 22 July 2026.

GastroAGI TeamRead more

5 min readJul 24, 202614reads

Complement C3 in the Tumor Microenvironment: A New Biomarker for Immunotherapy Response in Hepatocellular Carcinoma

A 61-year-old man with hepatitis B–related HCC starts atezolizumab-bevacizumab for unresectable disease. His PD-L1 status was never tested - it rarely changes management in HCC - and six months in, his tumor keeps growing while his neighbor on the same regimen, similar stage, similar liver function, gets a partial response. Nobody has a good answer for why. A new mechanism identified this month may finally explain part of that gap, and it has nothing to do with what's circulating in the blood. For years, complement C3 has been filed away as a liver-synthesized acute-phase protein whose main job is opsonizing pathogens in the bloodstream - relevant to sepsis and autoimmunity, not oncology. That framing is now incomplete. Researchers at Nagoya University, publishing in Nature Communications , found that C3 produced locally by cancer-associated fibroblasts inside the tumor microenvironment determines whether immune checkpoint blockade works, while circulating C3 levels made essentially no difference to outcomes. This distinction - tumor-produced versus liver-produced C3 - matters directly to hepatology, because the liver is both the primary site of systemic C3 synthesis and, in HCC, the organ where this local immune mechanism plays out. For a subspecialty already managing the first-line complement C3 hepatocellular carcinoma immunotherapy question through atezolizumab-bevacizumab, a locally-acting biomarker that blood tests won't detect changes what "checking the immune status of a tumor" should mean. How Local Complement C3 Shapes the Tumor Microenvironment The mechanism runs through myeloid cell trafficking, not T-cell priming. When C3 produced by fibroblasts within the tumor breaks down, it generates a fragment called iC3b, which blocks immunosuppressive myeloid cells from infiltrating the tumor stroma. Fewer suppressive myeloid cells in the tumor microenvironment HCC means checkpoint inhibitors have a clearer path to reactivating exhausted T cells. The research team confirmed the source-specificity experimentally in mice: reducing liver-derived circulating C3 by 90% barely touched anti-PD-1 efficacy, while silencing fibroblast-derived C3 within the tumor - despite only a 9% drop in blood C3 - sharply reduced how well the same antibody worked. That asymmetry is the finding worth sitting with. A hepatologist reflexively thinks of C3 as a liver synthesis product, and in the systemic sense it is. But the protein doing the immunologically relevant work in the tumor is made on-site, by fibroblasts, and behaves independently of whatever the liver is putting into circulation. Per the study, tumor tissue from lung cancer patients showed the same pattern clinically: roughly half of patients with high intratumoral C3 responded to immunotherapy, versus none of those with low levels - while blood C3 tracked with nothing. Case in Point A 58-year-old woman with MASH-related HCC, Child-Pugh A, BCLC stage B, is started on atezolizumab-bevacizumab after declining for locoregional therapy alone. Her baseline complement panel, drawn as part of a broader metabolic workup, shows normal serum C3. Nine months later, imaging shows progression despite an unremarkable inflammatory profile and no obvious resistance mechanism on standard workup. Retrospectively, this is exactly the scenario the Nagoya group's data would predict poorly: a normal systemic C3 tells you nothing about what her cancer-associated fibroblasts were producing locally. If tumor-tissue C3 or iC3b immunohistochemistry becomes clinically available, a case like hers is where it would earn its place - not as confirmation after the fact, but as a pre-treatment stratifier that a serum complement panel could never provide, since the two compartments dissociate almost entirely. What This Could Mean for HCC Treatment Selection None of this changes today's first-line regimen - atezolizumab-bevacizumab remains standard of care per IMbrave150, and no tissue-based complement assay has cleared validation for clinical use. What it does is open a biomarker pathway distinct from PD-L1 expression, tumor mutational burden, or the immune-based HCC subtyping schemes already in circulation, none of which have reliably predicted response at the individual-patient level. The mouse data go further than description: the research team tested a drug that mimics iC3b's myeloid-blocking effect and found it restored immunotherapy efficacy in tumors that had previously resisted treatment, extending survival significantly. That is the more consequential implication for immune checkpoint inhibitor resistance in HCC - not a better test to identify non-responders, but a potential add-on strategy to convert them into responders. For a disease where second-line options after checkpoint failure remain thin, a mechanism-matched combination agent, if it clears human trials, would be the more practice-changing outcome of the two. A tissue-based immunotherapy biomarker liver cancer assay is the more immediate translational step; the myeloid-blocking drug is the one worth watching over the next several years. A Frequently Overlooked Point The instinct in hepatology is to treat complement as a systemic marker of liver synthetic function - worth checking in the context of cirrhosis, sepsis, or autoimmune workups, and otherwise not particularly actionable in oncology. This data set argues that instinct now has a blind spot. iC3b myeloid cells trafficking is a tumor-local event, produced by stromal cells that have nothing to do with hepatic synthetic reserve, and a normal or even elevated serum complement panel provides no visibility into it. Until tissue-based assays exist, the honest clinical position is that we currently have no reliable way to know a given patient's intratumoral complement status - which is itself useful to communicate to a patient asking why the same drug worked for someone else and not for them. Bottom Line for Clinical Practice Serum complement C3 does not reflect intratumoral C3 activity - do not use a systemic complement panel to infer immunotherapy responsiveness in HCC. Tumor-produced C3, broken down locally into iC3b, blocks immunosuppressive myeloid cell infiltration and appears to be what determines checkpoint inhibitor efficacy at the tissue level. No validated clinical assay for intratumoral C3 or iC3b currently exists; atezolizumab-bevacizumab remains first-line per IMbrave150 regardless of complement status. Watch for translational work on iC3b-mimetic agents as a potential combination strategy for atezolizumab bevacizumab response in patients who progress on checkpoint blockade alone. When a patient's HCC isn't responding the way the literature says it should, the next question is rarely simple - and increasingly, the answer sits in the tumor microenvironment, not the chart. Walk GastroAGI through a case like this one, and it'll help you reason through what's actually driving non-response, guideline-anchored and current. Related Blog: GVAX Pancreatic Cancer Vaccine: What the 2026 Trial Data Means for PDAC Care Also Read: APASL 2026 Istanbul: Key Clinical Takeaways Every Hepatologist Needs to Know

GastroAGI TeamRead more

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

Gastroenterology Insights — Clinical Updates, Guides & Resources — Page 3

Ustekinumab for Fistulising Perianal Crohn’s Disease: What the GETAID Trial Adds to Clinical Practice

Maddrey's Discriminant Function: How to Calculate It Correctly

Artificial General Intelligence in Healthcare: What Gastroenterologists and Hepatologists Should Know Now

Rome V Criteria for IBS: What the New Frequency Threshold Actually Changes

Fluorescence-Guided Molecular Imaging in GI Oncology: What the AGA Lumicell Spotlight Signals for Future Cancer Resection

Should SNRIs Be Considered the Most Effective Neuromodulators for IBS? A Cautious Reading of the Evidence

Risk-Based Pathology Reporting After ESD for Early GI Cancer: New International Consensus Standards

New Diagnostic Criteria for Acute Severe Ulcerative Colitis: REFINED-ASUC Consensus for the Modern Treatment Era

Singing Therapy for Supragastric Belching: A Randomized Trial Challenges Conventional Breathing Therapy

Complement C3 in the Tumor Microenvironment: A New Biomarker for Immunotherapy Response in Hepatocellular Carcinoma

For You

Core Tools

Explore

Gastroenterology Insights — Clinical Updates, Guides & Resources — Page 3

Ustekinumab for Fistulising Perianal Crohn’s Disease: What the GETAID Trial Adds to Clinical Practice

Maddrey's Discriminant Function: How to Calculate It Correctly

Artificial General Intelligence in Healthcare: What Gastroenterologists and Hepatologists Should Know Now

Rome V Criteria for IBS: What the New Frequency Threshold Actually Changes

Fluorescence-Guided Molecular Imaging in GI Oncology: What the AGA Lumicell Spotlight Signals for Future Cancer Resection

Should SNRIs Be Considered the Most Effective Neuromodulators for IBS? A Cautious Reading of the Evidence

Risk-Based Pathology Reporting After ESD for Early GI Cancer: New International Consensus Standards

New Diagnostic Criteria for Acute Severe Ulcerative Colitis: REFINED-ASUC Consensus for the Modern Treatment Era

Singing Therapy for Supragastric Belching: A Randomized Trial Challenges Conventional Breathing Therapy

Complement C3 in the Tumor Microenvironment: A New Biomarker for Immunotherapy Response in Hepatocellular Carcinoma

For You

Core Tools

Explore